OncoMatch/Clinical Trials/NCT06702826
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
Is NCT06702826 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cadonilimab combined with SRS for non small cell lung cancer.
Treatment: Cadonilimab combined with SRS — The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC). The main questions it aims to answer are: * Does Cadonilimab combined with SRT in the second-line treatment of brain metastases provide better results? * Is the toxicity of Cadonilimab combined with SRT manageable in second-line treatment of brain metastases? Researchers will compare evaluate the efficacy and safety of Cadonilimab combined with SRT as a second-line treatment for patients with advanced NSCLC： * Receive Cadonilimab combined with SRT for brain lesions. * Visit the hospital regularly once every 12 weeks for checkups and tests
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: anti-tumor therapy — first-line
Progression with brain metastasis after previous first-line anti-tumor therapy
Must have received: checkpoint inhibitor
Response to previous checkpoint inhibitor therapy on the initial response assessment
Cannot have received: CTLA-4 inhibitor
Prior treatment with a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06702826 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CTLA-4 inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages